FIG. 2.

PRL suppresses EGF-induced MAPK (Erk1/Erk2)/RSK activation. Serum-starved differentiated HC11 cells (A) and NMuMG cells (B) were treated with PRL (P), EGF (E), or PRL/EGF (PE), as indicated. Cell lysates were immunoblotted with a polyclonal antibody to phospho-Erk1/Erk2 (upper panel) and Erk1/Erk2 (lower panel). (C) HC11 cell lysates prepared as in panels A and D. NMuMG cell lysates prepared as in panel B were immunoblotted with a polyclonal antibody to phospho-RSK (upper panel) and RSK (lower panel). WB, Western blot; α-, anti-.